Loading ...
Sorry, an error occurred while loading the content.

Fwd: NATA: DDW Reports

Expand Messages
  • claudine intexas
    Subject: NATA: DDW Reports NATAP http://natap.org/ _______________________________________________ DDW Digestive Disease Week May 21-24, 2006, Los Angeles
    Message 1 of 1 , May 26, 2006
    • 0 Attachment
      Subject: NATA: DDW Reports

      NATAP http://natap.org/
      _______________________________________________
      DDW
      Digestive Disease Week
      May 21-24, 2006, Los Angeles
      "...the most real-time, comprehensive, independent conference coverage on the internet..."
      Â These are reports from DDW so far posted on the NATAP website, others will be added.

      • "Week 12 Antiviral Activity of Higher Doses of albumin interferon alfa-2b (Albuferon) Combined with Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic HCV-Infection" - (05/25/06)
      Â
      • Entecavir (ETV) Demonstrates Consistent Responses Throughout Baseline Disease and Demographic Subgroups for the Treatment of Lamivudine-Refractory (LVD-ref) HBeAg(+) Patients with Chronic Hepatitis B - (05/25/06)
      Â
      • Final Analysis of Virological Outcomes and Resistance During 5 Years of adefovir Dipivoxil Monotherapy in HBeAg-Negative Patients - (05/25/06)
      Â
      • 96-Week Viral Suppression Data From Two Studies Presented For BARACLUDE (entecavir) In Chronically-Infected Hepatitis B Patients - (05/24/06)
      Â
      • Results from a Cost-Effectiveness Study Demonstrate Positive Economic Impact with PEGASYS Treatment - (05/24/06)
      Â
      • G-CSF is safe and improves adherence and SVR in HCV patients with genotype 1 who develop Peg-IFNa-2b related severe neutropenia - (05/24/06)
      Â
      • African-Americans' response to Interferon: preliminary results from Virahep C Study - (05/24/06)
      Â
      • VX-950 HCV Protease Inhibitor + Pegasys/RBV: 28 days study results in treatment-naive - (05/24/06)
      Â
      • ViroPharma Announces Presentation of HCV-796 Phase 1b Data at Digestive Disease Week - (05/23/06)
      Â
      • HCV Protease ITMN 191, In Vitro Resistance - - (05/23/06)
      Â
      • High Dose Albuferon -early data - (05/23/06)
      Â
      • Hepatitis Patients at Risk for Accidental Acetaminophen Toxicity - (05/23/06)
      Â
      • Reliable early prediction of viral relapse by detection of minimal residual hepatitis C viremia at treatment week 12 with Sensitive HCV Viral load Test - (05/22/06)
      Â
      • High Prevalence of Hepatitis C Virus Infection Among Russian Immigrants in the New York City Metropolitan Area: Results of A Community-Based Screening Program - (05/22/06)
      Â
      • Noninvasive Biomarker Test for Fatty Liver - (05/22/06)
      Â
      • Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients - (05/22/06)
      Â
      • The prevalence of metabolic syndrome (53%) in veterans with chronic hepatitis C virus - (05/22/06)
      Â


      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________


      ----------

      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________


      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.